drugset / Trial / NCT01311570

Study Assessing the Safety and Therapeutic Effect of Buprenorphine in MDD Patients

NCT01311570

Phase 1 Unknown 20 enrolled Shalvata Mental Health Center
NaSingle-groupOpen-labelTreatment

Summary

The primary objective of this study is to assess the therapeutic effect of Buprenorphine in MDD population. The secondary objectives of this study are to assess the therapeutic effect, the feasibility and safety of buprenorphine in a MDD population.

Timeline

Start
2012-10
Primary completion
2013-02
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Buprenorphine Other / unclassified 4 mg Other
Subject Buprenorphine Other / unclassified 8 mg Other

Indications